MedTrace Logo

Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002

NCT02118168 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 93

Last updated 2017-08-22

No results posted yet for this study

Summary

An observational study to prospectively follow-up the patients enrolled in the ISS T-002 clinical trial up to 132 weeks. The primary endpoint of this study is to evaluate the persistence, in term of frequency, magnitude and quality, of the anti-Tat humoral and cellular immune response in the HIV-1 infected individuals who participated to the ISS T-002 and who have received at least 3 immunizations. The secondary endpoint is to define and validate novel laboratory tests for future efficacy clinical trials.

Conditions

  • HIV Infection

Interventions

OTHER

No intervention

No intervention is foreseen in this Observational Study

Sponsors & Collaborators

  • Barbara Ensoli, MD, PhD

    lead OTHER

Principal Investigators

  • Barbara Ensoli, MD, PHD · Istituto Superiore di Sanità

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-07-31
Completion
2016-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02118168 on ClinicalTrials.gov